Devil's Advocate
Every policy has tradeoffs. Here are the strongest arguments against this proposal, presented in good faith. A robust policy must survive its best critics.
GATT Article III requires "national treatment"—imports must be treated no less favorably than domestic products. A levy explicitly targeting Chinese-origin drugs violates this on its face.
The "National Security" Exception Is Weak
Yes, the US can invoke GATT Article XXI national security exceptions. But this isn't about missiles or encryption—it's about cancer drugs. The WTO Panel in Russia—Traffic in Transit (2019) ruled that national security claims must be made in "good faith." Claiming a BTK inhibitor is a national security threat strains credulity.
Risk: China could file a WTO dispute and likely win on the merits. Even if the US ignores the ruling (as it often does), this provides ammunition for Chinese retaliation and damages US credibility on trade rules globally.
Chinese companies have developed genuinely innovative drugs that save American lives. Ivonescimab beat Keytruda in a head-to-head trial. CARVYKTI offers hope to multiple myeloma patients who've failed other treatments.
What if companies walk away?
If this levy makes US market economics unfavorable, Chinese companies might prioritize Europe, Japan, or emerging markets. The US patient loses.
Pipeline drugs at risk
50+ Chinese-origin drugs are in Phase 2/3 for the US market. Uncertainty around this levy could delay or cancel these programs.
The moral question: Should a cancer patient care whether their life-saving drug was invented in Suzhou or San Diego? We don't tax German cars to fund Detroit. Why tax Chinese drugs to fund Boston?
US pharma companies license Chinese drugs because they're good. Chinese biotechs are producing first-in-class assets in areas where US companies have struggled. ADCs, bispecifics, and novel cell therapies are flowing from China because that's where the innovation is happening.
The Licensing Math
US companies license Chinese drugs for a reason: it's cheaper and faster than developing them in-house. A levy changes this math. If BMS had to pay a 7% tax on BL-B01D1 revenues, would they have signed that $8.4B deal? Maybe they would have developed something inferior in-house—or nothing at all.
Perverse incentive: This levy punishes US companies for being efficient. It says: "You should have spent more money developing this yourself, even if Chinese scientists did it better and faster." That's not pro-innovation— it's protectionism dressed up as industrial policy.
Chinese biotechs are already using "NewCo" structures—spinning off assets into Delaware corporations where they retain minority stakes. Hengrui's Kailera deal put a 19.9% stake in a US-domiciled company. Is that "Chinese-origin"?
The Definition Problem
The BIOSECURE lesson: The original bill named specific companies. The final version had to use regulatory lists instead because gaming was obvious. This levy faces the same problem—but worse, because IP licensing is even more fluid than contract manufacturing.
Let's be honest about the numbers. Even the optimistic projections show:
| Net levy revenue (2030, after credits) | ~$1.3B |
| NIH annual budget | $48B |
| Levy as % of NIH | 2.7% |
| Average cost to develop one drug | $1.5B |
Reality check: This levy might fund development of one additional drug per year. Is that worth the trade friction, administrative complexity, WTO risk, and potential loss of Chinese innovation access? The cost-benefit doesn't pencil out.
China already controls 60%+ of global API production. If they wanted to retaliate, they have leverage:
Supply Chain
Market Access
Asymmetric risk: We're targeting ~$3B of Chinese drug revenue while exposing ourselves to retaliation on $100B+ of API supply. Even a modest Chinese response could cause drug shortages that dwarf any benefit from this levy.
If the goal is funding domestic R&D, why create a complex China-specific scheme when simpler options exist?
Just Increase NIH Funding
Congress appropriates $48B annually. Adding $1.3B is a 2.7% increase— a normal budget negotiation, not a trade war trigger.
Expand BARDA / ARPA-H
These agencies are already structured for targeted biotech investment. They don't need a new funding mechanism—they need bigger budgets.
Enhance R&D Tax Credits
The Section 41 R&D credit is ~6-8% effective rate. France offers 30%. Making US R&D more attractive doesn't require punishing foreign innovation.
Occam's Razor: The simplest explanation for why this levy exists isn't "to fund R&D." It's to make a political statement about China. If funding were the goal, direct appropriation is simpler, larger, and doesn't risk trade retaliation.
Once you establish that the US can levy taxes on drugs based on IP origin, what stops the next step?
Pandora's box: The EU, Japan, or India could retaliate with their own levies on US pharma IP. If "fund domestic R&D" is a valid justification, it works for everyone. Global pharma becomes a maze of origin-based taxes.
Let's be candid: anti-China sentiment is at historic highs. Politicians score points by being "tough on China." But good policy shouldn't be driven by what polls well—it should be driven by what works.
The BIOSECURE Pattern
BIOSECURE passed 306-81 because voting "no" on anything China-related is politically toxic. But policy made in this environment is rarely good policy. The companies named in the original bill (WuXi, BGI) were added based on vibes, not evidence. Due process concerns were raised and largely ignored.
Question the motive: Is this levy designed to optimize US biotech outcomes? Or is it designed to give politicians something to campaign on? The complexity of the scheme suggests the former; the China-specific targeting suggests the latter.
The pharmaceutical industry spent $378 million on lobbying in 2023. They filed 9+ lawsuits against the IRA. They will not accept a new levy quietly.
The Industry Argument
PhRMA will argue (correctly) that BMS, not BeiGene, bears most of this levy. American companies that licensed Chinese drugs get taxed. The Chinese licensor already got paid upfront. This is a tax on American pharmaceutical companies for being innovative enough to find good drugs wherever they are.
Prediction: PhRMA will propose amendments that gut the bill. Longer transition periods, lower rates, broader exemptions, weaker definitions. What passes (if anything) will be a shell of the original proposal.
A reasonable person could conclude: The costs and risks outweigh the modest benefits. The money should come from direct appropriation, not a complex scheme that invites gaming, retaliation, and legal challenge.
Note: This page presents the strongest case against CHINA PAYS in good faith. We believe robust policy should survive its best critics. For responses to these arguments, see the FAQ and full research.